Patients received oral cabozantinib 40 mg once daily and intravenous atezolizumab 1,200 mg once every 3 weeks. The primary end point was objective response rate (ORR), as assessed by the investigator ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback